Press Releases

Date Title and Summary View
Feb 10, 2014
MacroGenics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. , Feb. 10, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has
Additional Formats
Feb 05, 2014
MacroGenics Achieves Milestone as Servier Exercises Option to Develop and Commercialize DART-Based Candidate, MGD006
Successful Advancement of Lead DART Molecule and Option Exercise Triggers $20 Million in Payments MacroGenics Retains Full Rights to MGD006 in Multiple Major Markets ROCKVILLE, Md. and SURESNES, France , Feb. 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
Dec 11, 2013
MacroGenics Announces Publication of Cancer Stem Cell Research in Lung Cancer

Data Featured in PLOS ONE Contribute to MacroGenics' Platform to Identify Monoclonal Antibodies that Target Cancer Stem Cells

Additional Formats
Dec 09, 2013
MacroGenics Announces Presentation of Pre-Clinical Data on DART(R) Molecule Targeting CD123-Positive Leukemic Stem Cells at 55th Annual Meeting of the American Society of Hematology

Results Support Clinical Development of MGD006 in Hematologic Malignancies

Additional Formats
Nov 12, 2013
MacroGenics Provides Corporate Progress Update and Third Quarter 2013 Financial Results
ROCKVILLE, Md. , Nov. 12, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate
Additional Formats
Nov 11, 2013
MacroGenics to Present Pre-Clinical Data on Targeting CD123-Positive Leukemic Stem Cells at the 55th ASH Annual Meeting
ROCKVILLE, Md. , Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that
Additional Formats
Nov 11, 2013
MacroGenics DART Therapeutic Selected by Boehringer Ingelheim as a Bi-Specific Pre-Clinical Development Candidate

Selection of a Pre-Clinical Development Candidate Triggers a $5 Million Milestone Payment

Additional Formats
Nov 05, 2013
MacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call
ROCKVILLE, Md. , Nov. 5, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, November 12, 2013 , the Company will release its financial results for the third quarter ended September 30, 2013 . The Company's management team will host a conference call discussing
Additional Formats
Oct 16, 2013
MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option
ROCKVILLE, Md. , Oct. 16, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced the closing of its initial public offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to
Additional Formats
Oct 09, 2013
MacroGenics Announces Pricing of Initial Public Offering
MacroGenics Announces Pricing of Initial Public Offering ROCKVILLE, Md., October 9, 2013 - MacroGenics, Inc., today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $16.00 per share.
Additional Formats
Sep 19, 2013
MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman

Dr. David C. Stump to join company’s Board of Directors

Additional Formats
Aug 20, 2013
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271

Study to examine safety, pharmacokinetics and
anti-tumor effect of potential first-in-class B7-H3 targeted cancer immunotherapy

Additional Formats
Aug 12, 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development ROCKVILLE, Md., August 12, 2013 — MacroGenics, Inc. today announced that it has appointed Jon Wigginton, M.D., as Senior Vice President, Clinical Development. Dr.
Additional Formats
Jun 03, 2013
MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer
MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer ROCKVILLE, Md., June 3, 2013—MacroGenics, Inc.
Additional Formats
May 21, 2013
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer ROCKVILLE, Maryland - May 21, 2013/PRNewswire/ - MacroGenics, Inc.
Additional Formats
Jan 07, 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products

<ul>
<li>Based on MacroGenics&#8217; proprietary DART technology for generating bi-specific antibodies</li>
<li>Gilead receives rights to four pre-clinical programs</li>
<li>MacroGenics retains development and commercial rights to one of the programs in major markets outside North America and the European Union</li></ul>

Additional Formats
Sep 20, 2012
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products

<ul>
<li>Includes three novel pre-clinical programs for the treatment of solid and liquid tumors</li>
<li>Based on MacroGenics' proprietary DART technology for generating bi-specific antibodies that redirect the body's own immune system to kill cancer cells</li>
<li>MacroGenics retains full rights to each program in North America, Japan, Korea and India</li>
<li>Servier has the option to obtain exclusive license to develop and commercialize each program in the rest of the world</li></ul>

Additional Formats
Sep 05, 2012
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases Los Angeles, CA and Rockville, MD – September 5, 2012. ImaginAb, Inc.
Additional Formats
Dec 20, 2011
MacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim
ROCKVILLE , Maryland , December 20, 2011- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.   The milestone payment was triggered as part of an agreement
Additional Formats
Dec 01, 2011
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug

<ul>
<li>MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide variety of solid tumors</li>
<li>MacroGenics retains full program rights in North America, Japan, Korea and India</li>
<li>Servier has an option to obtain an exclusive license to develop and commercialize MGA271 in the rest of the world</li></ul>

Additional Formats
Jun 28, 2011
The Lancet Publishes Data from Protégé, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
ROCKVILLE , MD. , June 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protégé, a Phase 3 clinical study of teplizumab
Additional Formats
Jun 23, 2011
MacroGenics Announces Presentation of Protégé Phase 3 Clinical Data at ADA in San Diego on June 28
ROCKVILLE, MD., June 23 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protégé, the Company’s Phase 3 clinical study of teplizumab in type
Additional Formats
Apr 28, 2011
Data Published in Blood Demonstrate Potent Activity of MacroGenics' Proprietary DART™ Technology
ROCKVILLE , MD. , April 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent
Additional Formats
Jan 06, 2011
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-Expressing Solid Tumors
ROCKVILLE , MD. , January 6 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical
Additional Formats
Oct 26, 2010
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics INGELHEIM, Germany and ROCKVILLE, MD, USA, October 26, 2010 -- Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global
Additional Formats